KR20230007368A - 항-tmprss6 항체 및 이의 용도 - Google Patents

항-tmprss6 항체 및 이의 용도 Download PDF

Info

Publication number
KR20230007368A
KR20230007368A KR1020227038805A KR20227038805A KR20230007368A KR 20230007368 A KR20230007368 A KR 20230007368A KR 1020227038805 A KR1020227038805 A KR 1020227038805A KR 20227038805 A KR20227038805 A KR 20227038805A KR 20230007368 A KR20230007368 A KR 20230007368A
Authority
KR
South Korea
Prior art keywords
seq
ser
val
leu
tmprss6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227038805A
Other languages
English (en)
Korean (ko)
Inventor
신 두
부신 첸
유 진 왕
Original Assignee
맵웰 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 맵웰 테라퓨틱스 인크. filed Critical 맵웰 테라퓨틱스 인크.
Publication of KR20230007368A publication Critical patent/KR20230007368A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020227038805A 2020-04-07 2021-04-05 항-tmprss6 항체 및 이의 용도 Pending KR20230007368A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063006695P 2020-04-07 2020-04-07
US63/006,695 2020-04-07
US202163158265P 2021-03-08 2021-03-08
US63/158,265 2021-03-08
PCT/US2021/025775 WO2021207072A1 (en) 2020-04-07 2021-04-05 Anti-tmprss6 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20230007368A true KR20230007368A (ko) 2023-01-12

Family

ID=75888147

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227038805A Pending KR20230007368A (ko) 2020-04-07 2021-04-05 항-tmprss6 항체 및 이의 용도

Country Status (9)

Country Link
US (3) US12215170B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126220A1 (cg-RX-API-DMAC7.html)
JP (2) JP7813234B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230007368A (cg-RX-API-DMAC7.html)
CN (1) CN115243762B (cg-RX-API-DMAC7.html)
AU (1) AU2021251087A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174339A1 (cg-RX-API-DMAC7.html)
TW (1) TW202204422A (cg-RX-API-DMAC7.html)
WO (1) WO2021207072A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
US20230295345A1 (en) * 2020-04-07 2023-09-21 Mabwell Therapeutics, Inc. Anti-tmprss6 antibodies and uses thereof
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
KR20250128393A (ko) * 2022-11-25 2025-08-27 맵웰 테라퓨틱스 인크. 항-tmprss6 항체 및 그의 용도
CN120936629A (zh) * 2023-04-04 2025-11-11 迪斯克医药公司 抗tmprss6抗体及其用途
WO2024211900A1 (en) * 2023-04-06 2024-10-10 Memorial Sloan-Kettering Cancer Center Il-10 receptor antibodies and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
WO2005023835A2 (en) 2003-09-09 2005-03-17 Irm Llc Modulators of transmembrane protease serine 6
GB0614201D0 (en) 2006-07-18 2006-08-23 Univ Cardiff Matriptase-2
PE20130588A1 (es) 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
EP2776564B1 (en) * 2011-11-07 2019-10-02 Ionis Pharmaceuticals, Inc. Modulation of tmprss6 expression
AR093620A1 (es) * 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
CN106062004A (zh) 2013-12-17 2016-10-26 科马布有限公司 人靶标
WO2016071701A1 (en) * 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
AU2016302768B2 (en) * 2015-07-31 2019-08-22 Medimmune Limited Methods for treating hepcidin-mediated disorders
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
EP4065607A1 (en) 2019-11-29 2022-10-05 Kymab Limited Treatment for physiological iron overload
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
CA3216106A1 (en) 2021-04-26 2022-11-03 Alnylam Pharmaceuticals, Inc. Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
WO2022229150A1 (en) 2021-04-27 2022-11-03 Silence Therapeutics Gmbh Sirna targeting tmprss6 for the treawtment of myeloproliferative disorders

Also Published As

Publication number Publication date
EP4126220A1 (en) 2023-02-08
CN115243762B (zh) 2026-07-28
WO2021207072A1 (en) 2021-10-14
JP2026089058A (ja) 2026-05-29
CN115243762A (zh) 2022-10-25
JP7813234B2 (ja) 2026-02-12
US11866513B2 (en) 2024-01-09
CA3174339A1 (en) 2021-10-14
US20230203196A1 (en) 2023-06-29
TW202204422A (zh) 2022-02-01
AU2021251087A1 (en) 2022-12-01
JP2023520969A (ja) 2023-05-23
US12215170B2 (en) 2025-02-04
US20250304719A1 (en) 2025-10-02
US20230348623A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
CN110214154B (zh) 抗cd47抗体及其用途
EP2997042B1 (en) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
JP7813234B2 (ja) 抗tmprss6抗体及びその用途
RU2571224C2 (ru) Гуманизированные антитела против axl
KR102933484B1 (ko) 항-il-27 항체 및 그의 용도
KR102513989B1 (ko) 간 질환을 치료하거나 예방하는 방법
KR20190133160A (ko) 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
RU2744909C2 (ru) Способ лечения или предотвращения инсульта
KR20220080015A (ko) Alk7 결합 단백질 및 이들의 용도
KR20220016136A (ko) Alk7 결합 단백질 및 이의 용도
US20230295345A1 (en) Anti-tmprss6 antibodies and uses thereof
HK40079278A (en) Anti-tmprss6 antibodies and uses thereof
US20250136718A1 (en) Anti-tmprss6 antibodies and uses thereof
HK40104812A (en) Anti-tmprss6 antibodies and uses thereof
CN118078985A (zh) 抗tmprss6抗体及其用途
RU2790023C2 (ru) Способы лечения заболевания с применением ингибиторов костного морфогенетического белка 6 (вмр6)
KR20250128393A (ko) 항-tmprss6 항체 및 그의 용도
HK40013319B (en) Anti-cd47 antibody and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000